Given that FdUrd is active in ovarian cancer [44], [45], that defects in BRCA1 and BRCA2 (or other genes in the homologous repair pathway) are common in ovarian cancer [46], and that PARP inhibitors will likely have a role in the treatment of ovarian cancers [24], these findings suggested a novel therapeutic strategy in ovarian cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.